1 |
2020 |
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud. Current strategies for the design of PROTAC linkers: a critical review, Exploration of Targeted Anti-tumor Therapy. 2020; 1:
https://doi.org/10.37349/etat.2020.00018 |
2 |
2021 |
Ota Fuchs, Radka Bokorova. Preclinical Studies of PROTACs in Hematological Malignancies, Cardiovascular & Hematological Disorders-Drug Targets . 2021; 21: 7.
https://doi.org/10.2174/1871529X21666210308111546 |
3 |
2021 |
Moritz Fürstenau, Barbara Eichhorst. Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance, Cancers. 2021; 13: 1336.
https://doi.org/10.3390/cancers13061336 |
4 |
2022 |
Rachael Arthur, Alexander Wathen, Elizabeth A. Lemm, Freda K. Stevenson, Francesco Forconi, Adam J. Linley, Andrew J. Steele, Graham Packham, Beatriz Valle-Argos. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells, Cellular Signalling. 2022; 96: 110358110358.
https://doi.org/10.1016/j.cellsig.2022.110358 |
5 |
2022 |
Jingyu Zhang, Jinxin Che, Xiaomin Luo, Mingfei Wu, Weijuan Kan, Yuheng Jin, Hanlin Wang, Ao Pang, Cong Li, Wenhai Huang, Shenxin Zeng, Weihao Zhuang, Yizhe Wu, Yongjin Xu, Yubo Zhou, Jia Li, Xiaowu Dong. Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma, Journal of Medicinal Chemistry. 2022; 65: 9096.
https://doi.org/10.1021/acs.jmedchem.2c00324 |
6 |
2023 |
Manvendra Kumar, Joydeep Chatterjee, Dimpy Rani, Raj Kumar. 2023; 117.
https://doi.org/10.1016/B978-0-443-18616-5.00006-5 |
7 |
2022 |
Ota Fuchs, 2022; 71.
https://doi.org/10.1016/B978-0-323-90042-3.15001-7 |
8 |
2023 |
Yi-Qian Li, William G. Lannigan, Shabnam Davoodi, Fereidoon Daryaee, Ana Corrionero, Patricia Alfonso, Jose A. Rodriguez-Santamaria, Nan Wang, John D. Haley, Peter J. Tonge. Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy, Journal of Medicinal Chemistry. 2023; 66: 7454.
https://doi.org/10.1021/acs.jmedchem.3c00176 |
9 |
2023 |
Ana Portelinha, Hans-Guido Wendel. The cat-and-mouse game of BTK inhibition, Blood. 2023; 141: 1502.
https://doi.org/10.1182/blood.2022018936 |
10 |
2022 |
Matthew R. Burke, Alexis R. Smith, Guangrong Zheng. Overcoming Cancer Drug Resistance Utilizing PROTAC Technology, Frontiers in Cell and Developmental Biology. 2022; 10: 872729.
https://doi.org/10.3389/fcell.2022.872729 |
11 |
2023 |
Deyi Zhang, Hailey M. Harris, Jonathan Chen, Jen Judy, Gabriella James, Aileen Kelly, Joel McIntosh, Austin Tenn-McClellan, Eileen Ambing, Ying Siow Tan, Hao Lu, Stefan Gajewski, Matthew C. Clifton, Stephanie Yung, Daniel W. Robbins, Mehdi Pirooznia, Sigrid S. Skånland, Erika Gaglione, Maissa Mhibik, Chingiz Underbayev, Inhye E. Ahn, Clare Sun, Sarah E. M. Herman, Mark Noviski, Adrian Wiestner. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts, Blood. 2023; 141: 1584.
https://doi.org/10.1182/blood.2022016934 |
12 |
2022 |
Guangyan Du, Jie Jiang, Nathaniel J. Henning, Nozhat Safaee, Eriko Koide, Radosław P. Nowak, Katherine A. Donovan, Hojong Yoon, Inchul You, Hong Yue, Nicholas A. Eleuteri, Zhixiang He, Zhengnian Li, Hubert T. Huang, Jianwei Che, Behnam Nabet, Tinghu Zhang, Eric S. Fischer, Nathanael S. Gray. Exploring the target scope of KEAP1 E3 ligase-based PROTACs, Cell Chemical Biology. 2022; 29: 1470.
https://doi.org/10.1016/j.chembiol.2022.08.003 |
13 |
2021 |
Joel O. Cresser-Brown, Graham P. Marsh, Hannah J. Maple. Reviewing the toolbox for degrader development in oncology, Current Opinion in Pharmacology. 2021; 59: 43.
https://doi.org/10.1016/j.coph.2021.04.009 |